{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:35:47Z","timestamp":1791297347568,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,6,30]],"date-time":"2014-06-30T00:00:00Z","timestamp":1404086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"},{"start":{"date-parts":[[2014,6,30]],"date-time":"2014-06-30T00:00:00Z","timestamp":1404086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/srep05500","type":"journal-article","created":{"date-parts":[[2014,6,30]],"date-time":"2014-06-30T09:16:32Z","timestamp":1404119792000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["HE4 expression is associated with hormonal elements and mediated by importin-dependent nuclear translocation"],"prefix":"10.1038","volume":"4","author":[{"given":"Elizabeth","family":"Lokich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh K.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiro","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyukwang","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,6,30]]},"reference":[{"key":"BFsrep05500_CR1","unstructured":"Surveillance, Epidemiology and End Results (SEER) Program Populations (1969\u20132009). National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch. http:\/\/seer.cancer.gov\/statfacts\/html\/ovary.html Date of access: 06\/02\/2014."},{"key":"BFsrep05500_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ygyno.2004.03.026","volume":"94","author":"S Cunat","year":"2004","unstructured":"Cunat, S., Hoffmann, P. & Pujol, P. Estrogens and epithelial ovarian cancer. Gynecol Oncol 94, 25\u201332, 10.1016\/j.ygyno.2004.03.026 (2004).","journal-title":"Gynecol Oncol"},{"key":"BFsrep05500_CR3","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S1470-2045(13)70253-5","volume":"14","author":"W Sieh","year":"2013","unstructured":"Sieh, W. et al. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol 14, 853\u2013862, 10.1016\/S1470-2045(13)70253-5 (2013).","journal-title":"Lancet Oncol"},{"key":"BFsrep05500_CR4","doi-asserted-by":"publisher","first-page":"5722","DOI":"10.1073\/pnas.96.10.5722","volume":"96","author":"KM Lau","year":"1999","unstructured":"Lau, K. M., Mok, S. C. & Ho, S. M. Expression of human estrogen receptor-alpha and -beta, progesterone receptor and androgen receptor mRNA in normal and malignant ovarian epithelial cells. P Natl Acad Sci USA 96, 5722\u20135727 (1999).","journal-title":"P Natl Acad Sci USA"},{"key":"BFsrep05500_CR5","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1677\/erc.0.0070085","volume":"7","author":"AP Makar","year":"2000","unstructured":"Makar, A. P. Hormone therapy in epithelial ovarian cancer. Endocrin-Relat cancer 7, 85\u201393 (2000).","journal-title":"Endocrin-Relat cancer"},{"key":"BFsrep05500_CR6","first-page":"575","volume":"66","author":"DR Shirey","year":"1985","unstructured":"Shirey, D. R. et al. Tamoxifen therapy of epithelial ovarian cancer. Obstet Gynecol 66, 575\u2013578 (1985).","journal-title":"Obstet Gynecol"},{"key":"BFsrep05500_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/BF02685901","volume":"24","author":"H Karagol","year":"2007","unstructured":"Karagol, H. et al. The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer. Med Oncol 24, 39\u201343 (2007).","journal-title":"Med Oncol"},{"key":"BFsrep05500_CR8","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.ygyno.2009.01.012","volume":"113","author":"PA Argenta","year":"2009","unstructured":"Argenta, P. A. et al. A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer. Gynecol Oncol 113, 205\u2013209, 10.1016\/j.ygyno.2009.01.012 (2009).","journal-title":"Gynecol Oncol"},{"key":"BFsrep05500_CR9","doi-asserted-by":"publisher","first-page":"187","DOI":"10.12998\/wjcc.v1.i6.187","volume":"1","author":"Y Yokoyama","year":"2013","unstructured":"Yokoyama, Y. & Mizunuma, H. Recurrent epithelial ovarian cancer and hormone therapy. World J Clin Cases 1, 187\u2013190, 10.12998\/wjcc.v1.i6.187 (2013).","journal-title":"World J Clin Cases"},{"key":"BFsrep05500_CR10","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/1097-0142(19910715)68:2<269::AID-CNCR2820680209>3.0.CO;2-O","volume":"68","author":"KD Hatch","year":"1991","unstructured":"Hatch, K. D., Beecham, J. B., Blessing, J. A. & Creasman, W. T. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer 68, 269\u2013271 (1991).","journal-title":"Cancer"},{"key":"BFsrep05500_CR11","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.ygyno.2004.11.023","volume":"96","author":"R Zhou","year":"2005","unstructured":"Zhou, R., Treeck, O., Horn, F. & Ortmann, O. Effects of prolonged tamoxifen treatment on receptor expression and apoptosis of ovarian cancer cells. Gynecol Oncol 96, 678\u2013683, 10.1016\/j.ygyno.2004.11.023 (2005).","journal-title":"Gynecol Oncol"},{"key":"BFsrep05500_CR12","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1111\/j.1600-0854.2007.00579.x","volume":"8","author":"MJ Pryor","year":"2007","unstructured":"Pryor, M. J. et al. Nuclear localization of dengue virus nonstructural protein 5 through its importin alpha\/beta-recognized nuclear localization sequences is integral to viral infection. Traffic 8, 795\u2013807, 10.1111\/j.1600-0854.2007.00579.x (2007).","journal-title":"Traffic"},{"key":"BFsrep05500_CR13","doi-asserted-by":"publisher","first-page":"12053","DOI":"10.1021\/bi700521m","volume":"46","author":"GW Moseley","year":"2007","unstructured":"Moseley, G. W., Filmer, R. P., DeJesus, M. A. & Jans, D. A. Nucleocytoplasmic distribution of rabies virus P-protein is regulated by phosphorylation adjacent to C-terminal nuclear import and export signals. Biochemistry-US 46, 12053\u201312061, 10.1021\/bi700521m (2007).","journal-title":"Biochemistry-US"},{"key":"BFsrep05500_CR14","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/dvdy.20569","volume":"235","author":"CA Hogarth","year":"2006","unstructured":"Hogarth, C. A., Calanni, S., Jans, D. A. & Loveland, K. L. Importin alpha mRNAs have distinct expression profiles during spermatogenesis. Dev Dynam 235, 253\u2013262, 10.1002\/dvdy.20569 (2006).","journal-title":"Dev Dynam"},{"key":"BFsrep05500_CR15","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1042\/BJ20120150","volume":"443","author":"KM Wagstaff","year":"2012","unstructured":"Wagstaff, K. M., Sivakumaran, H., Heaton, S. M., Harrich, D. & Jans, D. A. Ivermectin is a specific inhibitor of importin alpha\/beta-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. Biochem J 443, 851\u2013856, 10.1042\/BJ20120150 (2012).","journal-title":"Biochem J"},{"key":"BFsrep05500_CR16","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1093\/annonc\/mdj047","volume":"17","author":"I Vergote","year":"2006","unstructured":"Vergote, I. & Abram, P. Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents. Ann Oncol 17, 200\u2013204, 10.1093\/annonc\/mdj047 (2006).","journal-title":"Ann Oncol"},{"key":"BFsrep05500_CR17","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1200\/JCO.2004.02.112","volume":"22","author":"A Howell","year":"2004","unstructured":"Howell, A. et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 22, 1605\u20131613, 10.1200\/JCO.2004.02.112 (2004).","journal-title":"J Clin Oncol"},{"key":"BFsrep05500_CR18","first-page":"417","volume":"8","author":"BJ Slotman","year":"1988","unstructured":"Slotman, B. J. & Rao, B. R. Ovarian cancer (review). Etiology, diagnosis, prognosis, surgery, radiotherapy, chemotherapy and endocrine therapy. Anticancer Res 8, 417\u2013434 (1988).","journal-title":"Anticancer Res"},{"key":"BFsrep05500_CR19","first-page":"3867","volume":"51","author":"AE Wakeling","year":"1991","unstructured":"Wakeling, A. E., Dukes, M. & Bowler, J. A potent specific pure antiestrogen with clinical potential. Cancer Res 51, 3867\u20133873 (1991).","journal-title":"Cancer Res"},{"key":"BFsrep05500_CR20","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1677\/erc.0.0090267","volume":"9","author":"C Morris","year":"2002","unstructured":"Morris, C. & Wakeling, A. Fulvestrant (\u2018Faslodex\u2019)--a new treatment option for patients progressing on prior endocrine therapy. Endocrin-Relat Cancer 9, 267\u2013276 (2002).","journal-title":"Endocrin-Relat Cancer"},{"key":"BFsrep05500_CR21","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.ygyno.2003.12.024","volume":"92","author":"NB Berry","year":"2004","unstructured":"Berry, N. B. et al. Transcriptional targeting in ovarian cancer cells using the human epididymis protein 4 promoter. Gynecol Oncol 92, 896\u2013904, 10.1016\/j.ygyno.2003.12.024 (2004).","journal-title":"Gynecol Oncol"},{"key":"BFsrep05500_CR22","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1093\/carcin\/21.12.2193","volume":"21","author":"T Yoshida","year":"2000","unstructured":"Yoshida, T. et al. Distinct mechanisms of loss of estrogen receptor alpha gene expression in human breast cancer: methylation of the gene and alteration of trans-acting factors. Carcinogenesis 21, 2193\u20132201 (2000).","journal-title":"Carcinogenesis"},{"key":"BFsrep05500_CR23","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/0092-8674(95)90228-7","volume":"83","author":"JL Counts","year":"1995","unstructured":"Counts, J. L. & Goodman, J. I. Alterations in DNA methylation may play a variety of roles in carcinogenesis. Cell 83, 13\u201315 (1995).","journal-title":"Cell"},{"key":"BFsrep05500_CR24","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrg1655","volume":"6","author":"KD Robertson","year":"2005","unstructured":"Robertson, K. D. DNA methylation and human disease. Nat Rev Genet 6, 597\u2013610, 10.1038\/nrg1655 (2005).","journal-title":"Nat Rev Genet"},{"key":"BFsrep05500_CR25","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1101\/gad.947102","volume":"16","author":"A Bird","year":"2002","unstructured":"Bird, A. DNA methylation patterns and epigenetic memory. Gene Dev 16, 6\u201321, 10.1101\/gad.947102 (2002).","journal-title":"Gene Dev"},{"key":"BFsrep05500_CR26","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/1752-0509-4-170","volume":"4","author":"F Gu","year":"2010","unstructured":"Gu, F. et al. Inference of hierarchical regulatory network of estrogen-dependent breast cancer through ChIP-based data. BMC Syst Biol 4, 170, 10.1186\/1752-0509-4-170 (2010).","journal-title":"BMC Syst Biol"},{"key":"BFsrep05500_CR27","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/(SICI)1097-0215(19980330)76:1<47::AID-IJC9>3.0.CO;2-Y","volume":"76","author":"A Ercoli","year":"1998","unstructured":"Ercoli, A. et al. Comparative study on the induction of cytostasis and apoptosis by ICI 182,780 and tamoxifen in an estrogen receptor-negative ovarian cancer cell line. Int J Cancer 76, 47\u201354 (1998).","journal-title":"Int J Cancer"},{"key":"BFsrep05500_CR28","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1038\/srep03574","volume":"4","author":"RG Moore","year":"2014","unstructured":"Moore, R. G. et al. HE4 (WFDC2) gene overexpression promotes ovarian tumor growth. Sci Rep 4, 3574, 10.1038\/srep03574 (2014).","journal-title":"Sci Rep"},{"key":"BFsrep05500_CR29","doi-asserted-by":"publisher","first-page":"40901","DOI":"10.1074\/jbc.M509347200","volume":"280","author":"Y Miyauchi","year":"2005","unstructured":"Miyauchi, Y. et al. Importin 4 is responsible for ligand-independent nuclear translocation of vitamin D receptor. J Biol Chem 280, 40901\u201340908, 10.1074\/jbc.M509347200 (2005).","journal-title":"J Biol Chem"},{"key":"BFsrep05500_CR30","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.bbrc.2009.09.093","volume":"390","author":"G Chachami","year":"2009","unstructured":"Chachami, G. et al. Transport of hypoxia-inducible factor HIF-1alpha into the nucleus involves importins 4 and 7. Biochem Bioph Res Co 390, 235\u2013240, 10.1016\/j.bbrc.2009.09.093 (2009).","journal-title":"Biochem Bioph Res Co"},{"key":"BFsrep05500_CR31","first-page":"17","volume":"3","author":"TS Lange","year":"2009","unstructured":"Lange, T. S. et al. Apoptotic and chemotherapeutic properties of iron (III)-salophene in an ovarian cancer animal model. Drug Des Devel Ther 3, 17\u201326 (2009).","journal-title":"Drug Des Devel Ther"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep05500.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep05500","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep05500.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T06:49:47Z","timestamp":1672987787000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep05500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,30]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,12,17]]}},"alternative-id":["BFsrep05500"],"URL":"https:\/\/doi.org\/10.1038\/srep05500","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,30]]},"assertion":[{"value":"11 March 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.G.M. and R.K.S. are listed as co-inventors on a patent (US61\/493881). Patent was assigned to Women and Infants Hospital of Rhode Island. Other authors declare that no competing interest exists.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5500"}}